Driven by scientific vision and grounded in collaboration, Iovance Biotherapeutics is establishing leadership in immuno-oncology by developing Tumor-Infiltrating Lymphocyte (TIL) technology to deliver personalized therapies to patients with unmet medical needs. Actively recruiting phase 2 trials in metastatic melanoma, cervical cancer, squamous cell carcinoma of the head and neck and NSCLC.